Supply Chain Management in Pharma: Pharmaceutical Contract Packaging as a Regulatory Asset

Regulatory affairs usually appears in the supply chain conversation as a cost line and a delay: something to satisfy before product can move, owned by another function, discussed after the network is designed.

That sequencing is backwards. In pharmaceutical contract packaging, regulatory position is not a constraint applied to a supply chain. It is one of the variables that determines what the supply chain can be: where product enters a market, how it is routed, which markets it can reach at all, and how late you can still change what a pack says.

Treated properly, regulatory capability shortens lead times. Treated as an overhead, it becomes the reason a launch slips a quarter.

Regulatory constraints are supply chain design decisions

Where QP release happens decides where product can enter a market

A batch reaches a market through the point at which a Qualified Person certifies it. That point is a physical site named on a licence, and it anchors the flow. Site the certification badly and you build in transport legs, double handling and quarantine time that no freight optimisation recovers.

The commercial question is simple: how many days sit between goods-in and saleable stock, and how many are documentation review rather than physical work? A partner with QP capacity and product familiarity compresses that number. A partner with one QP and a queue does not.

Importation status decides routing

Product manufactured outside the UK must be imported by a site holding an MIA that authorises importation, and certified by a QP at that site. If your packer is not a site of importation, someone else has to be, which adds an organisation, a transfer and a handoff.

Central Pharma is both a Site of Importation and a Site of QP Release, with three Qualified Persons releasing product to more than 60 countries, so import, pack, certify and despatch happen in one quality system rather than across several.

Serialisation capability decides which markets you can serve

There is currently no mandatory medicines serialisation scheme for the UK domestic market. EU Falsified Medicines Directive safety features ceased to apply in Great Britain on 1 January 2021 and, under the Windsor Framework, in Northern Ireland from 1 January 2025, with EU 2D codes and serial numbers removed or covered for the NI market.

Serialisation is therefore an export capability for UK packers, not a domestic obligation. It is what lets UK-packed product reach the EU, which requires a unique identifier in a 2D DataMatrix, an anti-tampering device and upload to the European Medicines Verification System, and the United States, where the DSCSA stabilisation period ended on 27 May 2026 and aggregation with EPCIS 1.2 or later data exchange became enforceable on 28 May 2026. Every case must now report the unit serials it contains, and every pallet the case serials.

A packer without aggregation and data management cannot lawfully feed those chains. Central Pharma runs serialisation with in-house specialists covering ATD application, full aggregation and reworking data management for global directives.

Licence scope decides what you can do late in the chain

The activities listed on a licence set the boundary of late-stage flexibility. Rework and repack of finished product, relabelling of vials and ampoules, kitting, inspection: each is either authorised or it is not. When a pack turns out to carry the wrong destination artwork, a site that can lawfully rework gives you a two-week fix. A site that cannot gives you a write-off.

Late-stage differentiation and multi-market launches

The strongest argument for regulatory capability in the packing partner is postponement. Hold product in bulk or in unlabelled primary packs and commit it to a market only when demand is visible. Every day differentiation is delayed is forecast accuracy gained.

That works only if the partner can carry out the differentiating step under licence, apply the correct market artwork, serialise to the destination requirement and certify the batch. Postponement without those four in one place is inventory sitting further upstream.

Artwork, pack change and the cost of a market variant

Multi-market supply generates artwork versions faster than most organisations can control them. Each market has its own statutory text, language and layout requirements, and UK product now needs its own outer carton: all medicines placed on the UK market must carry "UK Only" labelling at a minimum of 7-point font, and joint EU/UK packs have not been permitted since 1 January 2025.

Version control is therefore a supply chain control, not a marketing one: one controlled artwork register, a defined approval route with named approvers, physical segregation of superseded components, reconciliation at line clearance. Getting it wrong produces the most avoidable rework there is.

Variations carry a supply chain lead time

A change to a pack, a site, a supplier or a specification is a regulatory variation, and variations have assessment timelines that sit on the critical path. The failure mode is predictable: the operational change is planned around implementation feasibility, the submission is treated as a parallel task, and the product cannot be sold on the day the line is ready. A partner who reads the change from both sides raises the sequencing question early: what needs approval first, what can proceed under change control, and when the first compliant batch becomes saleable.

Site transfers and requalification

Moving a product between packing sites is not a logistics exercise. It brings equipment and process qualification, possibly stability data, method transfer, artwork requalification, revised technical agreements and a variation. That burden is worth carrying when the destination site removes structural friction, by combining importation, packing, serialisation and QP release. It is rarely worth carrying to save a few pence a pack.

Shortages, recalls and rework under scrutiny

Disruption is where regulatory capability earns its keep. A shortage response may need a rapid repack, a market swap or an import of alternative supply. A recall needs a documented, time-bound process under GDP with regulator notification and traceability to consignee level. Rework needs authorised activity, a written rationale, reconciliation and QP judgement on the reworked batch. Ask what happened the last time a partner ran an urgent rework, and who made the release decision.

Separate UK and EU release

UK and EU market supply are now separate release paths. Batches for the EU market require certification by a QP in the EU or EEA; UK market batches are certified under a UK MIA. Companies serving both need to know which route a batch is on before it is packed, because artwork, serialisation and certification follow from that decision.

The technical agreement is the instrument that defines responsibility

Everything above lands in one document. The technical agreement allocates GMP responsibility between contract giver and contract acceptor: who approves artwork, who investigates deviations, who certifies, who holds retained samples, who notifies regulators, who owns the recall decision. A thin technical agreement is unallocated risk waiting for the worst moment.

Key takeaways

• QP release location and importation status determine where product can lawfully enter a market and how it is routed.
• With no mandatory UK domestic scheme, serialisation is an export capability that gates access to EU FMD and US DSCSA markets.
• Late-stage differentiation delivers only if the partner can pack, label, serialise and certify to the destination market under its own licence.
• Variations, site transfers and artwork changes carry regulatory lead time that belongs in the supply chain plan, not after it.
• The technical agreement is where responsibility for artwork, deviations, certification and recall is defined.

Talk to Central Pharma about regulatory-led supply

Central Pharma combines pharmaceutical contract packaging with the regulatory capability that decides what a supply chain can do: a Site of Importation and Site of QP Release with three Qualified Persons, serialisation and aggregation for global directives, regulatory support, dedicated project management and release to more than 60 countries, from one Bedford site under MHRA MIA and WDA(H). For a partner who removes regulatory friction rather than adding a handoff, get in touch.

To stay informed on our latest thinking and technology developments, follow us on LinkedIn.

Contact Us Today

View all news